Found: 29
Select item for more details and to access through your institution.
Validation of a risk prediction model for early chronic kidney disease in patients with type 2 diabetes: Data from the German/Austrian Diabetes Prospective Follow‐up registry.
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 3, p. 776, doi. 10.1111/dom.14925
- By:
- Publication type:
- Article
Effectiveness and safety of early insulin glargine administration in combination with continuous intravenous insulin infusion in the management of diabetic ketoacidosis: A randomized controlled trial.
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 3, p. 815, doi. 10.1111/dom.14929
- By:
- Publication type:
- Article
Objective sleep characteristics and continuous glucose monitoring profiles of type 2 diabetes patients in real‐life settings.
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 3, p. 823, doi. 10.1111/dom.14930
- By:
- Publication type:
- Article
Front Cover.
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 3, p. C1, doi. 10.1111/dom.14995
- By:
- Publication type:
- Article
Back Cover.
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 3, p. C4, doi. 10.1111/dom.14996
- By:
- Publication type:
- Article
Diabetes, Obesity and Metabolism.
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 3, p. 637, doi. 10.1111/dom.14750
- Publication type:
- Article
Metabolic and physiological responses to graded exercise testing in individuals with type 1 diabetes using insulin pump therapy.
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 3, p. 878, doi. 10.1111/dom.14938
- By:
- Publication type:
- Article
Peripherally restricted oxytocin is sufficient to reduce food intake and motivation, while CNS entry is required for locomotor and taste avoidance effects.
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 3, p. 856, doi. 10.1111/dom.14937
- By:
- Publication type:
- Article
Reduction of cardiac adipose tissue volume with short‐term empagliflozin treatment in patients with type 2 diabetes: A substudy from the SIMPLE randomized clinical trial.
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 3, p. 844, doi. 10.1111/dom.14933
- By:
- Publication type:
- Article
Safety, tolerability, pharmacodynamics and pharmacokinetics following once‐daily doses of BI 187004, an inhibitor of 11 beta‐hydroxysteroid dehydrogenase‐1, over 28 days in patients with type 2 diabetes mellitus and overweight or obesity
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 3, p. 832, doi. 10.1111/dom.14932
- By:
- Publication type:
- Article
A phase 1 study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of danuglipron (PF‐06882961), an oral small‐molecule glucagon‐like peptide‐1 receptor agonist, in Japanese adults with type 2 diabetes mellitus
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 3, p. 805, doi. 10.1111/dom.14928
- By:
- Publication type:
- Article
Effects of intensive blood pressure lowering in patients with diabetes: A pooled analysis of the STEP and ACCORD‐BP randomized trials.
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 3, p. 796, doi. 10.1111/dom.14927
- By:
- Publication type:
- Article
Efficacy and safety of janagliflozin as add‐on therapy to metformin in Chinese patients with type 2 diabetes inadequately controlled with metformin alone: A multicentre, randomized, double‐blind, placebo‐controlled, phase 3 trial.
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 3, p. 785, doi. 10.1111/dom.14926
- By:
- Publication type:
- Article
Age‐dependent prevalence of type 2 diabetes, cardiovascular risk profiles and use of diabetes drugs in Germany using health claims data.
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 3, p. 767, doi. 10.1111/dom.14924
- By:
- Publication type:
- Article
Cardiorenal outcomes by indices of liver steatosis and fibrosis in individuals with type 2 diabetes and atherosclerotic cardiovascular disease: Analyses from VERTIS CV, a randomized trial of the sodium‐glucose cotransporter‐2 inhibitor ertugliflozin
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 3, p. 758, doi. 10.1111/dom.14923
- By:
- Publication type:
- Article
Model‐based predictions on health benefits and budget impact of implementing empagliflozin in people with type 2 diabetes and established cardiovascular disease.
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 3, p. 748, doi. 10.1111/dom.14921
- By:
- Publication type:
- Article
Medical and surgical treatment of postbariatric hypoglycaemia: Retrospective data from daily practice.
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 3, p. 735, doi. 10.1111/dom.14920
- By:
- Publication type:
- Article
Burden of established cardiovascular disease in people with type 2 diabetes and matched controls: Hospital‐based care, days absent from work, costs and mortality.
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 3, p. 726, doi. 10.1111/dom.14919
- By:
- Publication type:
- Article
Liver fat is superior to visceral and pancreatic fat as a risk biomarker of impaired glucose regulation in overweight/obese subjects.
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 3, p. 716, doi. 10.1111/dom.14918
- By:
- Publication type:
- Article
The challenges and pitfalls of incorporating evidence from cardiovascular outcomes trials in health economic modelling of type 2 diabetes.
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 3, p. 639, doi. 10.1111/dom.14917
- By:
- Publication type:
- Article
Chronic kidney disease begets heart failure and vice versa: temporal associations between heart failure events in relation to incident chronic kidney disease in type 2 diabetes.
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 3, p. 707, doi. 10.1111/dom.14916
- By:
- Publication type:
- Article
Effect of finerenone on the occurrence of vision‐threatening complications in patients with non‐proliferative diabetic retinopathy: Pooled analysis of two studies using routine ophthalmological examinations from clinical trial participants (ReFineDR/DeFineDR)
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 3, p. 894, doi. 10.1111/dom.14915
- By:
- Publication type:
- Article
Impact of the CamAPS FX hybrid closed‐loop insulin delivery system on sleep traits in older adults with type 1 diabetes.
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 3, p. 889, doi. 10.1111/dom.14914
- By:
- Publication type:
- Article
Comparison of two titration programmes for adding insulin detemir to oral antidiabetic drugs in patients with poorly controlled type 2 diabetes mellitus.
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 3, p. 700, doi. 10.1111/dom.14912
- By:
- Publication type:
- Article
Weight management in young adults with type 1 diabetes: The advancing care for type 1 diabetes and obesity network sequential multiple assignment randomized trial pilot results.
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 3, p. 688, doi. 10.1111/dom.14911
- By:
- Publication type:
- Article
Nomogram model and risk score to predict 5‐year risk of progression from prediabetes to diabetes in Chinese adults: Development and validation of a novel model.
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 3, p. 675, doi. 10.1111/dom.14910
- By:
- Publication type:
- Article
A multicentre, randomized, double‐blind, parallel, active‐ and placebo‐controlled Phase 3 clinical study of the glucokinase activator PB‐201 in treatment‐naive patients with type 2 diabetes mellitus: A study protocol.
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 3, p. 649, doi. 10.1111/dom.14909
- By:
- Publication type:
- Article
Safety and efficacy of liraglutide on reducing visceral and ectopic fat in adults with or without type 2 diabetes mellitus: A systematic review and meta‐analysis.
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 3, p. 664, doi. 10.1111/dom.14908
- By:
- Publication type:
- Article
Findings for iGlarLixi versus BIAsp 30 confirmed in groups of people with type 2 diabetes with different biomedical characteristics.
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 3, p. 656, doi. 10.1111/dom.14907
- By:
- Publication type:
- Article